Basic Information
Baergic Bio is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of CNS diseases. Its pipeline currently includes the single compound BAER-101, an orally administered small-molecule selective GABA-A α2/3 receptor positive allosteric modulator licensed from AstraZeneca.
Baergic Bio, Inc.
NewYork,NewYork,United States of America
unclear
December 01, 2019
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios